Prostatic urethral lift

Penn Highlands Healthcare Physician Embraces Robotic Technology: First In Region To Robotically Remove a Bladder and Create a Urinary Diversion

Retrieved on: 
Tuesday, December 5, 2023
Urine, General surgery, Bleeding, The Jetsons, Urethra, Lymph, Movement, Bladder cancer, Robotics, Male, Surgeon, Star Wars, Prostate cancer, Green-light, MD, Urinary diversion, Prostate, System, Ureteroscopy, Constriction, Prostatic urethral lift, Scar, Television, Cancer, Patient, Medicine, Female, R2-D2

Dr. Banerji recently completed his100th robotic case, which was a radical prostatectomy – surgery to remove the entire prostate gland and surrounding lymph nodes -- on a man with localized prostate cancer.

Key Points: 
  • In 2021, surgeons at Penn Highlands Healthcare began using the advanced da Vinci Xi robotic-assisted surgical system to perform a wide range of delicate and complex operations.
  • Today, in addition to being used for general surgery, the da Vinci robot is assisting surgeons who perform urologic, colorectal and gynecologic surgeries at Penn Highlands DuBois.
  • John S. Banerji, MD, a physician with Penn Highlands Urology in Clearfield and DuBois, Pennsylvania, has been using the robotic-assisted system for his surgeries.
  • While some surgeons remove the bladder robotically and then convert to open surgery for the urinary diversion, Dr. Banerji performed the entire surgical procedure robotically.

New Data Highlight that Early Intervention with the UroLift® System Facilitates Long-Term Outcomes for BPH Patients

Retrieved on: 
Wednesday, May 3, 2023
TURP, University, BPH, AUA, Catheter, PUL, LUTS, International Prostate Symptom Score, Quality of life, American Urological Association, PVR, TFX, Research, Prostate, Prostatic urethral lift, MIST, NYSE, Lower urinary tract symptoms, MD, Patient, Urology, Urinary retention, Annual general meeting, PVP, Cystoscopy, PSA, IPSS, Disease, Medical imaging, Nursing

PUL with the UroLift® System was durable in most subjects at one and five years.

Key Points: 
  • PUL with the UroLift® System was durable in most subjects at one and five years.
  • In surgical therapy patients, procedure complication rates were lowest for the UroLift® System (17%) and highest for Rezūm™ (28%).
  • “As clinicians listen to their patients’ goals, technological advances are allowing them to deliver treatments that reflect those priorities better than ever before.
  • The data presented at AUA reinforce the importance of earlier intervention in BPH and the UroLift® System as an effective and durable BPH solution that improves patients’ quality of life and supports a superior patient experience.”1-3

Olympus Highlights Minimally Invasive Treatment Options at AUA

Retrieved on: 
Monday, April 24, 2023
Science, ASC, Elective surgery, Mini, CMS, Suction, OPPS, Centers for Medicare & Medicaid Services, Urine, Cancer, BPH, AUA, University of Michigan Institute for Social Research, PUL, Olympus, Center for Medicare and Medicaid Innovation, American Urological Association, Bladder cancer, Prostatic urethral lift, Urinary tract infection, Quality of life, Olympus Corporation, Multimedia, Endoscopy, Prostate, Medicare, Plasma, Lower urinary tract symptoms, Patient, Blood, Kidney, Prospective payment system, APC, Safety, Laparoscopy, Medical device, Birth control, Health insurance, Online shopping

CENTER VALLEY, Pa., April 24, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, will highlight its minimally invasive portfolio for the treatment of enlarged prostate, urinary stones and bladder cancer during the American Urology Association (AUA) annual meeting April 28-May 1 in Chicago.

Key Points: 
  • The Olympus booth will feature hands-on demonstrations of:
    ShockPulse-SE™ system, SOLTIVE™ Premium SuperPulsed Laser System and EMPOWER™ laser for kidney and bladder stone management.
  • A versatile electrode portfolio for plasma resection and vaporization for the treatment of BPH and bladder tumors, including the PlasmaButton™ and PlasmaLoop™ electrodes.
  • Olympus will also highlight its expanded stone management portfolio, including the Mini-PCNL system and new stone retrieval baskets.
  • Visit the Olympus booth, #3015, during AUA and the urology product page for information on the complete urology portfolio.

UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH

Retrieved on: 
Monday, March 13, 2023
Human, Benign prostatic hyperplasia, Transurethral microwave thermotherapy, Research, EAU, NYSE, International Prostate Symptom Score, Prostatic urethral lift, Quality of life, Patient, Congress, Prostate, Lower, National Association Medical Staff Services, BPH, Safety, SHIM, IPSS, Erectile dysfunction, PUL, TURP, PVP, TFX, OML, Pharmaceutical industry, Nursing, Medical imaging, Teleflex, Urology

WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world studies of the Prostatic Urethral Lift (PUL) procedure with the UroLift® System, for treating men with benign prostatic hyperplasia (BPH). Results underscore the benefits of early intervention with respect to durability, symptom improvement and sexual function that urologists around the world have come to expect from the UroLift® System, which is the leading minimally invasive, outpatient treatment in the United States for enlarged prostate.1 The research was presented at the 38th Annual European Association of Urology (EAU) Congress taking place in Milan from March 10-13, 2023.

Key Points: 
  • “These important new analyses show that, whether compared to other interventions or medication, the UroLift® System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms,” said Jacqueline Welch, Vice President, Global Clinical and Scientific Operations, Teleflex.
  • Following are key findings from the studies:
    PUL with the UroLift® System was durable in most subjects at one and five years.
  • Additionally, only these TURP subjects experienced high-severity adverse events.4
    Outcomes from the largest healthcare utilization study for BPH therapies, including medication5
    Procedure complication rates were similar between TURP, Photoselective Vaporization of the Prostate (PVP) and Aquablation®, and lowest for PUL with the UroLift® System.
  • “The results from these studies emphasize the value of the UroLift® System in successfully treating BPH symptoms, enabling rapid recovery, preserving sexual function, and improving patients’ overall quality of life.”2-5

Teleflex Earns Top Spot in MedReps Best Places to Work 2023 Ranking

Retrieved on: 
Monday, November 21, 2022
Urology, Culture, Teleflex, Organization, Corporation, Patient, Radiology, TFX, Annual report, Anesthesia, Weck, Core values, Security (finance), Prostatic urethral lift, NYSE, Health, Emergency medicine, LMA, Management, Risk management, QuikClot

Its great to be named a Best Place to Work for the sixth consecutive year, said Liam Kelly, Chairman, President, and CEO at Teleflex.

Key Points: 
  • Its great to be named a Best Place to Work for the sixth consecutive year, said Liam Kelly, Chairman, President, and CEO at Teleflex.
  • Teleflex employees are committed to living our Core Values and putting people at the center of everything we do.
  • Employees have a choice on where they work, and we are proud that they choose to work with Teleflex.
  • To learn more about the MedReps Best Places to Work 2023 Report, click here.

Teleflex Announces Worldwide Recall of Gibeck® Iso-Gard® Filter

Retrieved on: 
Thursday, November 3, 2022
Online, Fax, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Letter, Probability, FDA, Prostatic urethral lift, Anesthesia, Urology, Weck, Radiology, Annual report, ET, U.S. Securities and Exchange Commission, Injury, LMA, Desaturation, Quarantine, Health, Filter, Security (finance), Emergency medicine, Patient, Solution, Medical device, Teleflex, QuikClot

Teleflex initiated this voluntary recall on August 29, 2022 due to reports received indicating that the device split or detached during use.

Key Points: 
  • Teleflex initiated this voluntary recall on August 29, 2022 due to reports received indicating that the device split or detached during use.
  • Teleflex is currently issuing an expansion to this recall to include additional lots.
  • Teleflex requests that users immediately check their inventory for product within the scope of this recall.
  • On October 14, 2022, the U.S. Food and Drug Administration (FDA) classified the recall of Gibeck Iso-Gard Filters as a Class I recall.

BPH Treatment Market to Cross $18,837.7 Million Value by 2030: P&S Intelligence

Retrieved on: 
Tuesday, November 1, 2022
Population, BPH, Percussion section, Income, Research, Laser, Standard of care, CAGR, Investment, Medicine, Prostatic urethral lift, Patient, Man, Prevalence, Prostate, Burns, Male, Renewable energy, Health insurance, Medical imaging, Medscape

NEW YORK, Nov. 1, 2022 /PRNewswire/ --According to the latest market research study published by P&S Intelligence, the BPH treatment market accounted for $11,892.8 million revenue in 2021, which is set to touch $18,837.7 million by 2030, progressing at a 5.2% CAGR from 2021 to 2030.

Key Points: 
  • NEW YORK, Nov. 1, 2022 /PRNewswire/ --According to the latest market research study published by P&S Intelligence, the BPH treatment market accounted for $11,892.8 million revenue in 2021, which is set to touch $18,837.7 million by 2030, progressing at a 5.2% CAGR from 2021 to 2030.
  • This is owing to the growing cases of BPH, soaring preference for minimally invasive operations, and snowballing investments for research on novel treatments.
  • As per Medscape, by the age of 60, approximately 50% of the men develop histopathologic BPH.
  • Browse detailed report on Benign Prostatic Hyperplasia Treatment Market Size, Share and Demand Analysis Report 2022-2030
    North America holds a 41% share of the globalBPH treatment market.

Published Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings

Retrieved on: 
Tuesday, October 25, 2022
Pelvic pain, Prostatic urethral lift, Bleeding, General manager, Infection, Clinical trial, Anesthesia, Paper, NYSE, Patient, Patient satisfaction, BPH, IPSS, American Urological Association, Emergency medicine, Â, Solution, PUL, Prostate, Radiology, Teleflex, Health, Hematuria, Association, TURP, Safety, GLOBE, European Association of Urology, Heat, FDA, IDE, TFX, Pharmaceutical industry, Medical imaging, Health insurance, Dysuria, Urology, Man

WAYNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced today new data published in the peer-reviewed Journal of Endourology demonstrate the minimally invasive Prostatic Urethral Lift (PUL) procedure using the UroLift® System yields consistent safety, effectiveness and patient experience outcomes for benign prostatic hyperplasia (BPH) with and without obstructive median lobes.

Key Points: 
  • Ejaculatory function scores for men treated with the UroLift System were also significantly better than TURP at all timepoints.
  • PUL for obstructive median lobes in a real-world setting confirms controlled clinical trial results following treatment with the UroLift System.
  • Symptom and uroflow outcomes were largely consistent for obstructive median lobe patients treated in controlled and real-world settings; however, patients treated in a real-world setting experienced fewer post-operative catheterizations without elevated adverse events.
  • Furthermore, real-world safety, symptom and patient experience outcomes were equivalent between men with lateral and median lobe obstruction.

Georgia Urology expands provider roster by adding three physicians to acclaimed team

Retrieved on: 
Thursday, October 6, 2022
Physician, Incontinence, Vasectomy, DiCarlo, Medicine, Saint Louis University, University, Woman, General surgery, University of Virginia School of Medicine, Laparoscopy, Patient, Green-light, BPH, Erectile dysfunction, Man, American Urological Association, Multimedia, Medical college, Urology, Men's Health, Prostate, DRS, Prostatic urethral lift, Medical College of Georgia, CEO, University of Texas Health Science Center at San Antonio, Health, Pediatrics, Virginia School for Girls, Infertility, Kidney stone disease, Urinary incontinence, Solution, Medical device, Dentistry

ATLANTA, Oct. 6, 2022 /PRNewswire/ -- Georgia Urology – the largest urology practice in Georgia – welcomes Drs. Vincent DiCarlo, Robert Fisher, and Kanika Searvance to its acclaimed team of providers. With this expansion, Georgia Urology continues to provide accessibility and diversity to the array of communities it serves.

Key Points: 
  • ATLANTA, Oct. 6, 2022 /PRNewswire/ -- Georgia Urology the largest urology practice in Georgia welcomes Drs.
  • "At Georgia Urology, our team of talented and enthusiastic medical professionals have a deep passion for patient care and urology," says Dan Fellner, CEO of Georgia Urology.
  • "We're honored to welcome Dr. DiCarlo, Dr. Fisher, and Dr. Searvance to that team, each of whom exemplifies those qualities."
  • Georgia Urology is the largest urology practice in Georgia with more than 30 locations and seven ambulatory surgery centers across metro Atlanta.

Teleflex Completes Acquisition of Standard Bariatrics

Retrieved on: 
Wednesday, September 28, 2022
Weck, Health, NYSE, Legislation, Anesthesia, Company, Acquisition, LMA, Achievement, U.S. Securities and Exchange Commission, Patient, Emergency medicine, Medicaid, Solution, Annual report, Teleflex, EPS, Bariatric surgery, Stock dilution, Security (finance), GLOBE, Prostatic urethral lift, Urology, Bariatrics, TFX, Radiology, Health insurance, Medicare, QuikClot

WAYNE, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Standard Bariatrics, Inc., which has commercialized an innovative powered stapling technology for bariatric surgery.

Key Points: 
  • WAYNE, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Standard Bariatrics, Inc., which has commercialized an innovative powered stapling technology for bariatric surgery.
  • On August 22, Teleflex announced its entry into a definitive agreement to acquire Standard Bariatrics.
  • Under the terms of the agreement, Teleflex acquired Standard Bariatrics for $170 million at closing, with additional consideration of up to $130 million payable upon the achievement of certain commercial milestones.
  • Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.